Skip to main content

Love Bread & Pasta? Humans' Hunger for Carbs Has Ancient Roots

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 18, 2024.

By Dennis Thompson HealthDay Reporter

FRIDAY, Oct. 18, 2024 -- Folks who struggle to reduce their carb intake might be able to blame ancient DNA still lurking in humans, a new study suggests.

Humans carry multiple copies of the salivary amylase gene (AMY1), which helps begin breaking down starch in the mouth -- the first step in digesting carb-laden foods like bread and pasta, researchers said.

The duplication of this gene might have occurred as far back as more than 800,000 years ago, long before the advent of farming, and it helped shape human adaptation to starchy foods, researchers argue.

Amylase is an enzyme that breaks down starch into glucose, and it also gives bread its distinctive taste, researchers said.

"The idea is that the more amylase genes you have, the more amylase you can produce and the more starch you can digest effectively,” said researcher Omer Gokcumen, a professor of biological sciences with the University of Buffalo.

For the study, researchers analyzed the genetics of 68 ancient human bodies, including a person who lived 45,000 years ago in Siberia.

They found that pre-agricultural hunter-gatherers carried an average of four to eight AMY1 copies in their genetic makeup, suggesting that people already had adapted to eating starchy foods long before they began growing foods like wheat and potatoes.

AMY1 gene duplications also were found in ancient human ancestors like Neanderthals and Denisovans, the researchers added.

“This suggests that the AMY1 gene may have first duplicated more than 800,000 years ago, well before humans split from Neanderthals and much further back than previously thought,” said researcher Kwondo Kim, a postdoctoral associate with the Jackson Laboratory for Genomic Medicine.

These initial duplications of the AMY1 gene “allow[ed] humans to adapt to shifting diets as starch consumption rose dramatically with the advent of new technologies and lifestyles,” Gokcumen said in a lab news release.

As humans spread around the world, the flexibility in the number of AMY1 copies allowed them to adapt to new diets, depending on the environment around them, researchers said.

Farming further altered human genetics. European farmers saw a surge in the average number of AMY1 copies over the past 4,000 years, likely driven by their starch-rich diets.

"Individuals with higher AMY1 copy numbers were likely digesting starch more efficiently and having more offspring,” Gokcumen said. “Their lineages ultimately fared better over a long evolutionary timeframe than those with lower copy numbers, propagating the number of the AMY1 copies."

The new study was published Oct. 17 in the journal Science.

This research could have practical, real-world consequences for modern humans suffering from obesity and type 2 diabetes, researchers said.

“Given the key role of AMY1 copy number variation in human evolution, this genetic variation presents an exciting opportunity to explore its impact on metabolic health and uncover the mechanisms involved in starch digestion and glucose metabolism,” said researcher Feyza Yilmaz, an associate computational scientist at the Jackson Laboratory. “Future research could reveal its precise effects and timing selection, providing critical insights into genetics, nutrition and health.”

Sources

  • Jackson Laboratory for Genomic Medicine, news release, Oct. 17, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

FDA Launches Postmarket Chemical Review Program to Ensure Food Safety

MONDAY, May 19, 2025 -- Last week, the U.S. Food and Drug Administration announced a move to improve transparency and strengthen the safety of chemicals used in the nation's food...

GLP-1 Drugs Appear To Lower Cancer Risk

MONDAY, May 19, 2025 — Cutting-edge GLP-1 weight-loss drugs appear to help lower cancer risk even beyond the benefits from dropping excess pounds, a new study...

Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills

FRIDAY, May 16, 2025 — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.